PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.

Go online to PeerView.com/UDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly in recent years, and research endeavors continue to expand treatment options with significant implications for patients. In addition to the approval of multiple second-generation androgen deprivation therapies (ADTs), current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. Furthermore, when managing patients with mCSPC, clinicians must consider established, newly approved, and emerging therapies, as well as individual patient-, tumor-, and treatment-related factors. Given the wealth of new options, how do clinicians determine the best treatment course for each patient? Answers to this and other thought-provoking queries are provided in this educational activity based on a recent live symposium, as a panel of prostate cancer experts examine the latest clinical data for novel and emerging therapeutic approaches and discuss evidence-based strategies for individualizing treatment for each patient with mCSPC. Upon completion of this activity, participants should be better able to: Assess the rationale and clinical evidence for novel therapeutic approaches for patients with mCSPC, such as the addition of novel androgen axis inhibitors or docetaxel to ADT, Develop optimal, individualized treatment plans for patients with mCSPC that incorporate novel therapeutics as appropriate, taking into consideration individual patient-, disease-, and treatment-related factors, Apply evidence- and team-based strategies to proactively mitigate and manage treatment-related adverse events that may occur in patients with mCSPC who are receiving novel therapeutics as part of their care, Employ effective strategies to engage patients with mCSPC in shared decision-making, with the goal of maximizing patient satisfaction, clinical outcomes, and treatment adherence.

Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.